Investigating respiratory infection as a post-COVID-19 condition using a large passive surveillance cohort from Track PCC.

Publication date: Jul 16, 2026

This study examined risk factors for post-COVID respiratory infection using data from the Tracking the Burden, Distribution, Impact of Tracking Post-COVID-19 Conditions in Diverse Populations for Children, Adolescents, Adults (Track PCC) passive surveillance cohort. This retrospective study included adult Temple Health patients in Philadelphia, Pennsylvania with SARS-CoV-2 (COVID-19) infections from March 2020 to December 2022 and ≥ 90 days follow-up. COVID-19 infection was identified via laboratory testing, billing codes, or clinical documentation. The primary outcome was post-COVID respiratory infection identified by billing codes. Predictors included social, clinical, and COVID-related correlates. Adjusted logistic regression models were used on 17,539 complete cases and multiple imputed datasets (n = 45,513) with SuperMICE. In complete-case analysis, uninsured coverage, Alpha variant, total comorbidities, and hospitalization were associated with lower odds of respiratory post-COVID conditions (ORs: 0. 02-0. 99). Dual Medicare/Medicaid and current smokers, increased odds (ORs: 1. 33-1. 58). Imputed analyses showed consistent results with and additionally observed higher odds of respiratory infection among those with Medicaid and higher number of vaccinations, and lower odds among those of any non-white race, Hispanic ethnicity. Temple Track PCC findings identify high-risk populations and underscore the utility of advanced imputation in surveillance-based research.

Open Access PDF

Concepts Keywords
EHR
Long COVID
Medical record
Post-COVID conditions
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Factor IX Complex (Human)
disease MESH PCC
disease MESH included
disease MESH infections
disease MESH post-COVID conditions
disease MESH Infectious Diseases
disease MESH Dis
pathway REACTOME Reproduction
drug DRUGBANK Methylphenidate
disease MESH Respiratory infections
disease MESH inflammation
disease MESH fibrosis
disease MESH ICD
disease MESH overweight

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *

Investigating respiratory infection as a post-COVID-19 condition using a large passive surveillance cohort from Track PCC.

Publication date: Jul 16, 2026

This study examined risk factors for post-COVID respiratory infection using data from the Tracking the Burden, Distribution, Impact of Tracking Post-COVID-19 Conditions in Diverse Populations for Children, Adolescents, Adults (Track PCC) passive surveillance cohort. This retrospective study included adult Temple Health patients in Philadelphia, Pennsylvania with SARS-CoV-2 (COVID-19) infections from March 2020 to December 2022 and ≥ 90 days follow-up. COVID-19 infection was identified via laboratory testing, billing codes, or clinical documentation. The primary outcome was post-COVID respiratory infection identified by billing codes. Predictors included social, clinical, and COVID-related correlates. Adjusted logistic regression models were used on 17,539 complete cases and multiple imputed datasets (n = 45,513) with SuperMICE. In complete-case analysis, uninsured coverage, Alpha variant, total comorbidities, and hospitalization were associated with lower odds of respiratory post-COVID conditions (ORs: 0. 02-0. 99). Dual Medicare/Medicaid and current smokers, increased odds (ORs: 1. 33-1. 58). Imputed analyses showed consistent results with and additionally observed higher odds of respiratory infection among those with Medicaid and higher number of vaccinations, and lower odds among those of any non-white race, Hispanic ethnicity. Temple Track PCC findings identify high-risk populations and underscore the utility of advanced imputation in surveillance-based research.

Open Access PDF

Concepts Keywords
EHR
Long COVID
Medical record
Post-COVID conditions
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Factor IX Complex (Human)
disease MESH PCC
disease MESH included
disease MESH infections
disease MESH post-COVID conditions
disease MESH Infectious Diseases
disease MESH Dis
pathway REACTOME Reproduction
drug DRUGBANK Methylphenidate
disease MESH Respiratory infections
disease MESH inflammation
disease MESH fibrosis
disease MESH ICD
disease MESH overweight

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *